Assenagon Asset Management S.A. Boosts Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Assenagon Asset Management S.A. grew its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 55.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 475,446 shares of the biotechnology company's stock after buying an additional 168,813 shares during the period. Assenagon Asset Management S.A. owned approximately 1.74% of AnaptysBio worth $15,927,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Ensign Peak Advisors Inc increased its position in AnaptysBio by 74.4% in the 2nd quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company's stock valued at $1,898,000 after buying an additional 32,313 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $420,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of AnaptysBio during the first quarter worth approximately $1,221,000. Alpha DNA Investment Management LLC bought a new position in shares of AnaptysBio in the 2nd quarter worth $399,000. Finally, nVerses Capital LLC grew its position in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares during the period.

AnaptysBio Price Performance

Shares of AnaptysBio stock traded down $0.19 during trading hours on Friday, hitting $32.03. 712,602 shares of the company's stock traded hands, compared to its average volume of 325,534. The company has a fifty day simple moving average of $35.45 and a 200-day simple moving average of $29.78. The stock has a market capitalization of $875.03 million, a price-to-earnings ratio of -5.22 and a beta of -0.29. AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, analysts forecast that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares of the company's stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Paul F. Lizzul sold 1,500 shares of the business's stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares of the company's stock, valued at $189,333.04. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is owned by company insiders.

Analyst Ratings Changes

ANAB has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of AnaptysBio in a research note on Wednesday, August 14th. Guggenheim raised their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Truist Financial boosted their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. JPMorgan Chase & Co. raised their target price on AnaptysBio from $69.00 to $75.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. Finally, Wedbush reiterated an "outperform" rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $54.64.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.